Abstract
Platelets have a crucial role in the maintenance of normal haemostasis, and perturbations of this system can lead to pathological thrombus formation and vascular occlusion, resulting in stroke, myocardial infarction and unstable angina. ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb–IIIa and subsequent binding of fibrinogen. ADP is also secreted from platelets on activation, providing positive feedback that potentiates the actions of many platelet activators1. ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes2,3. The P2Y1 receptor couples to Gq and mobilizes intracellular calcium ions to mediate platelet shape change and aggregation4,5. The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi. The molecular identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel6,7,8 and AR-C66096 (ref. 9). Here we describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder10 has a defect in this gene. Cloning of the P2Y12 receptor should facilitate the development of better antiplatelet agents to treat cardiovascular diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mills, D. C. ADP receptors on platelets. Thromb. Haemost. 76, 835–856 (1996).
Jantzen, H. M. et al. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb. Haemost. 81, 111–117 (1999).
Daniel, J. L. et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273, 2024–2029 ( 1998).
Leon, C. et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J. Clin. Invest. 104, 1731–1737 ( 1999).
Fabre, J. E. et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nature Med. 5, 1199–1202 (1999).
Gachet, C. et al. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem. Pharmacol. 40, 2683–2687 (1990).
Gachet, C. et al. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes—an effect selectively blocked by the thienopyridine clopidogrel. Thromb. Haemost. 68 , 79–83 (1992).
Mills, D. C. B. et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase Arterioscler. Thromb. 12, 430–436 ( 1992).
Humphries, R. G., Tomlinson, W., Ingall, A. H., Cage, P. A. & Leff, P. A novel, highly potent and selective antagonist at human platelet P2T-purinoreceptors. Br. J. Pharmacol. 113, 1057–1063 (1994).
Nurden, P. et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J. Clin. Invest. 95, 1612–1622 (1995).
Krapivinsky, G., Krapivinsky, L., Wickman, K. & Clapham, D. Gβγ binds directly to the G protein-gated K+ channel, IKACh. J. Biol. Chem. 270, 29059– 29062 (1995).
Ohlmann, P. et al. The human platelet ADP receptor activates Gi2 proteins. Biochem. J. 312, 775–779 (1995).
MacFarlane, D. E., Srivastava, P. C. & Mills, D. C. B. 2-Methylthioadenosine[β-32P]diphosphate: an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J. Clin. Invest. 71, 420–428 (1983).
Hourani, S. M. O. & Hall, D. Receptors for ADP on human blood platelets. Trends Pharmacol. Sci. 15 , 103–108 (1994).
Jantzen, H.-M. et al. Evidence for two distinct G protein-coupled ADP receptors mediating platelet activation. Blood 92, 303a (1998).
Boyer, J. L., Romero-Avila, T., Schachter, J. B. & Harden, T. K. Identification of competitive antagonists of the P2Y1 receptor. Mol. Pharmacol. 50, 1323– 1329 (1996).
Palmer, R. K., Boyer, J. L., Schachter, J. B., Nicholas, R. A. & Harden, T. K. Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol. Pharmacol. 54, 1118–1123 (1998).
Filippov, A. K., Brown, D. A. & Barnard, E. A. The P2Y1 receptor closes the N-type Ca2+ channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists. Br. J. Pharmacol. 129, 1063–1066 (2000).
Boyer, J. L., Lazarowski, E. R., Chen, X. H. & Harden, T. K. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J. Pharmacol. Exp. Ther. 267, 1140– 1146 (1993).
Stewart, E. et al. An STS-based radiation hybrid map of the human genome. Genome Res. 7, 422–433 ( 1997).
Chambers, J. K. et al. A G protein-coupled receptor for UDP-glucose. J. Biol. Chem. 275, 10767–10771 (2000).
Savi, P. et al. Identification and biological activity of the active metabolite of Clopidogrel. Thromb. Haemost. (in the press)
Cattaneo, M. & Gachet, C. ADP receptors and clinical bleeding disorders. Arterioscler. Thromb. Vasc. Biol. 19, 2281–2285 (1999).
Jarvis, G. E., Humphries, R. G., Robertson, M. J. & Leff, P. ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors. Br. J. Pharmacol. 129, 275– 282 (2000).
Hechler, B., Eckly, A., Ohlmann, P., Cazenave, J.-P. & Gachet, C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br. J. Haematol. 103, 858–866 (1998).
Humbert, M. et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler. Thromb. Vasc. Biol. 16, 1532–1543 (1996).
Bennett, C. L. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. 325, 1371– 1372 (2000).
Caterina, M. J. et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816– 824 (1997).
Acknowledgements
We thank E. Peralta for advice and encouragement. We also thank H. Chuang for advice with electrophysiological assays; A. Laibelman and R. Scarborough for C1330-7; P. Castro and L. Komuves for assistance and advice with the in situ hybridization; the Oksenberg and Reijo laboratories for human DNA samples; E. Thompson, K. Simpson, S. Hollenbach and K. Ministri-Madrid and the COR animal facility for technical assistance; R.Wong and D. De Guzman for assistance with figures; and C. Homcy, E. E. Reynolds, J. Topper and D. Phillips for discussions. D.J. is supported by funding from NIH and NIMH; G.H. is supported by a NIH predoctoral neuroscience training grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hollopeter, G., Jantzen, HM., Vincent, D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202–207 (2001). https://doi.org/10.1038/35051599
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35051599
This article is cited by
-
Blood oxygen regulation via P2Y12R expressed in the carotid body
Respiratory Research (2024)
-
A general alkene aminoarylation enabled by N-centred radical reactivity of sulfinamides
Nature Chemistry (2024)
-
Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
BMC Biology (2023)
-
Pharmacological characterization of P2Y receptor subtypes – an update
Purinergic Signalling (2023)
-
The Function and Regulation of Platelet P2Y12 Receptor
Cardiovascular Drugs and Therapy (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.